TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18630536
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral administration of Betaloc and Oryzanol)
Study: 29273130
Drug: Birch subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch subcutaneous allergen immunotherapy (AIT) for 24 months
Study: 29273130
Drug: Birch subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch subcutaneous allergen immunotherapy (AIT)
Study: 26562368
Drug: Early HepB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early HepB (administered within a few hours after birth)
Study: 26562368
Drug: Late HepB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late HepB (administered after the repeat CRP)
Study: 24934774
Drug: 20mg diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg diazepam nasal spray (NS)
Study: 24934774
Drug: 20mg diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg diazepam rectal gel (RG)
Study: 24934774
Drug: Both intranasal
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intranasal and rectal treatments
Study: 9802271
Drug: Self-supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-supervised treatment (retreatment patients)
Study: 9802271
Drug: Direct observation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct observation (DO) treatment (retreatment patients)
Study: 31419597
Drug: Linguistically‐based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linguistically‐based treatment of passive sentence production and comprehension (N = 14, treatment group)
Study: 24373522
Drug: Expectation-induced placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation-induced placebo (wound gel)
Study: 24373522
Drug: Non-active gel
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active gel (control group)
Study: 16454838
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg b.i.d.
Study: 8545745
Drug: Hypoxoside (1,200‐3,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxoside (1,200‐3,200 mg standardized Hypoxis plant extract per day divided in 3 doses)
Study: 2322638
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release capsules of 120 mg administered every 12 h
Study: 27348402
Drug: Breathing a
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing a hyperoxic gas mixture with a constant fraction of 60% inhaled oxygen during exercise training
Study: 27894777
Drug: Long-acting-release octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting-release octreotide (20 mg intramuscularly, 2 doses, 4 weeks before and on the day of surgery)
Study: 21488717
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump (SAP) therapy
Study: 15350001
Drug: Molecular adsorbents
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular adsorbents recirculating system (MARS) therapy over 7 days
Study: 23341981
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) alone
Study: 15350001
Drug: MARS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARS therapy
Study: 11598598
Drug: Calcium-fortified cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified cereal (156 mg/serving)
Study: 11598598
Drug: Low-calcium cereal
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium cereal (39 mg/serving)
Study: 30635055
Drug: silybin-phosphatidylcholine complex
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: silybin-phosphatidylcholine complex (45 mg)
Study: 18823212
Drug: Aural presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aural presentation of nonwords with unattested onsets (e.g., bnif, bdif, lbif)
Study: 10673994
Drug: Infusional 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusional 5-FU therapy (B1, B2, B3 regimens)
Study: 27402817
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of atorvastatin
Study: 18287255
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa once weekly
Study: 11127783
Drug: Complementary Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary Medicine (CM)
Study: 9367398
Drug: IVIG infusions
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG infusions during placebo phase
Study: 9367398
Drug: IVIG infusions
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG infusions during nhuIL-2 treatment phase
Study: 26538428
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing (PGx)
Study: 22685047
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g dark chocolate daily for 7 weeks
Study: 17875243
Drug: PR-melatonin (Circadin*
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-melatonin (Circadin* 2 mg), one tablet per day at 2 hours before bedtime
Study: 17875243
Drug: PR-melatonin (Circadin*
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-melatonin (Circadin* 2 mg)
Study: 12090325
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg/day) and azathioprine (100 mg/day) for four months
Study: 1370924
Drug: t‐PA (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA (60 mg in the first hour and a maintenance infusion of 13.3 mg/hr for 3 hours)
Study: 6376145
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glipizide (meal + glipizide)
Study: 27620884
Drug: Surgical glove
Normalized name: Astrapro Surgical Gloves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical glove (SG) compression therapy
Study: 3302924
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mg/kg every six hours)
Study: 23959376
Drug: Desensitizing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agent (5% potassium nitrate, 2% sodium fluoride)
Study: 18402848
Drug: Unlimited free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unlimited free emergency contraceptive pills (ECPs) in advance of need
Study: 18402848
Drug: Standard access
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard access to emergency contraceptive pills (ECPs)
Study: 15806544
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg/day) plus antibiotics
Study: 15806544
Drug: Antibiotics without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics without G-CSF
Study: 3071619
Drug: Nilvadipine 4
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 4 mg 3 times a day
Study: 3071619
Drug: Nilvadipine 4
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 4 mg twice a day
Study: 11230635
Drug: Gadobutrol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobutrol (1.0 mol/L) injected intravenously at doses of 0.1 or 0.3 mmol/kg
Study: 29873107
Drug: Food Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Food Insulin Index
Study: 19089749
Drug: Coffeeberry (CB)
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffeeberry (CB) supplementation at a dose of 800 mg per day for 4 weeks
Study: 14602757
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg
Study: 7479216
Drug: No erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No erythropoietin treatment
Study: 453783
Drug: Orally given
Normalized name: TITANIUM DIOXIDE 7.75 g in 100 mL / ZINC OXIDE 10 g in 100 mL TOPICAL CREAM [Give Me Shade Sunscreen Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally given analgesic-spasmolytic combination preparation (Group II)
Study: 453783
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication, Group III)
Study: 25240532
Drug: Canakinumab 10
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 10 mg/kg
Study: 8912230
Drug: ipsapirone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (20 mg)
Study: 29153975
Drug: Empirical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antimicrobial therapy (EAT) withdrawn after 72 hours of apyrexia plus clinical recovery.
Study: 23689809
Drug: Metronidazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (15 to 20 mg/kg per day for 3 months)
Study: 19229497
Drug: CBT SL-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT SL-5 lotion (containing cell-free culture supernatant of E. faecalis SL-5)
Study: 8255556
Drug: Amphetamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine administration (oral and intramuscular)
Study: 3518724
Drug: Ibopamine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (200-300 mg single oral dose)
Study: 30742244
Drug: Anti-TNF-α treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α treatment (group B)
Study: 30742244
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) and sulfasalazine (SSZ) (group A)
Study: 20851549
Drug: 3-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-h infusion of imipenem/cilastatin
Study: 12887823
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ramipril and Losartan
Study: 3823619
Drug: Bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200 mg t.i.d.)
Study: 6740281
Drug: Duck embryo
Normalized name: Duck
DrugBank: Duck (DB10610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duck embryo rabies vaccine (DEV), administered according to the prescribed schedule (14 initial inoculations and 3 boosters)
Study: 25237116
Drug: CBD 300
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 3000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 300 mg/day
Study: 31560051
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vancomycin (OVP) 125 mg once daily for 5 days post-systemic antibiotics
Study: 31560051
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vancomycin (OVP)
Study: 24794368
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (4 mg/kg/d for 2 weeks) and oral prednisolone (2 mg/kg/d for 2 weeks) followed by a tapering protocol for 9 weeks
Study: 24794368
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone and oral prednisolone
Study: 27262892
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy of the involved shoulder for 10 weeks
Study: 27262892
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy of the uninvolved shoulder for 10 weeks (Control group)
Study: 20334449
Drug: Individualized antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized antithrombotic therapy
Study: 12243609
Drug: Selective serotonin-reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin-reuptake inhibitors (SSRIs)
Study: 8565089
Drug: 6-month short-course
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month short-course chemotherapy
Study: 24194532
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IT) for 2 weeks
Study: 17980093
Drug: Combined 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 0.5% moxifloxacin and 0.1% dexamethasone formulation (Vigadexa)
Study: 7595165
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after 64-week treatment period
Study: 2147859
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 25-50 mg/day + ethinyl-estradiol (EE) 20-30 micrograms/day
Study: 2147859
Drug: SPL +
Normalized name: Salmeterol plus fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL + bromocriptine (2.5-5 mg/day)
Study: 2147859
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) alone or associated with tamoxifen (100 mg + 100 mg/day)
Study: 24132190
Drug: Warfarin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (in patients with prior MI)
Study: 19359647
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering treatment (Perindopril)
Study: 12577435
Drug: Qingwei Zhitong
Normalized name: METHYL SALICYLATE 13 g / MENTHOL 9 g / CAMPHOR (SYNTHETIC) 11 g TOPICAL PATCH [KGS Zhitong Gao Medicated Plaster Extra Strength]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingwei Zhitong pill (QWZTP)
Study: 12577435
Drug: Sifangwei tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifangwei tablet
Study: 24152974
Drug: DelpHi-Intervention conducted
Normalized name: Delphinium staphisagria preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DelpHi-Intervention conducted by Dementia Care Managers (DCMs) with dementia-specific training; details on dosage and duration not specified.
Study: 19216048
Drug: Family‐based cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐based cognitive‐behavioral therapy (FCBT)
Study: 1504111
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg yohimbine
Study: 30972871
Drug: Dr. Wolff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dr. Wolff Gel (test gel)
Study: 30972871
Drug: Biotene (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotene (control gel)
Study: 19858419
Drug: CRT on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT on (active therapy)
Study: 9151927
Drug: YNK-01 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YNK-01 at 200 mg/d
Study: 9151927
Drug: YNK-01 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YNK-01 at 300 mg/d
Study: 7476236
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with parasite derived antigen (94‐67 KD)
Study: 7476236
Drug: Antimonial therapy
Normalized name: antimony
DrugBank: Antimony (DB13110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimonial therapy
Study: 1282182
Drug: Nicorandil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (30 mg)
Study: 2525330
Drug: Diltiazem (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (low-dose 60 mg)
Study: 28095801
Drug: Small‐quantity lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Study: 26248034
Drug: Sildenafil citrate®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil citrate® 100 mg for 2-3 times per week in addition to intensive glycemic control
Study: 19756419
Drug: Thrice-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily dosing of 200 mg/kg per day ceftazidime
Study: 15063387
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lycopene/day (Group A)
Study: 1569443
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Study: 1569443
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Study: 17914351
Drug: Biocompatible dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible dialysis solutions (B)
Study: 17914351
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis solutions (S)
Study: 16157429
Drug: Inactivated, trivalent,
Normalized name: Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland)
Study: 12881345
Drug: 0.5% levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levofloxacin ophthalmic solution
Study: 8981915
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (r-hGH; 2.0 IU/d)
Study: 1536016
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml (2.0 mg) of chymopapain
Study: 6342219
Drug: Low maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low maintenance dose of prednisone (30 mg/day) and antilymphocyte globulin (ALG)
Study: 6342219
Drug: High maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance doses of prednisone (2 mg/kg/day with tapering) and intravenous methylprednisolone (IVMP)
Study: 29228935
Drug: Nebulized 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 2.0% morphine
Study: 9568649
Drug: Single antibiotic
Normalized name: BACITRACIN ZINC 500 [iU] in 1 g TOPICAL OINTMENT [Single Antibiotic]
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single antibiotic agent treatment in group A
Study: 9568649
Drug: Triple-agent antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-agent antibiotics in group B
Study: 8041524
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spatula and swab
Study: 21595877
Drug: Systematic program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic program for increasing influenza vaccine uptake among HCWs
Study: 12701008
Drug: Endoscopic epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic epinephrine injection therapy
Study: 9363412
Drug: Clonidine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (maximum daily dose: 0.6 mg)
Study: 30736383
Drug: Mangiferin +
Normalized name: mangiferin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangiferin + Luteolin (PHE: 50 mg/day; MLE: 140 mg/day)
Study: 30736383
Drug: Mangiferin +
Normalized name: mangiferin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangiferin + Luteolin (PHE: 100 mg/day; MLE: 420 mg/day)
Study: 16732060
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (ICRT) with 17 Gy
Study: 1351673
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Triazolam (0.250 mg)
Study: 1351673
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Zopiclone (7.5 mg)
Study: 3241278
Drug: Hydrochlorothiazide (diuretic)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (diuretic)
Study: 23332861
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 μg
Study: 30469433
Drug: hypothermic histidine‐tryptophan‐ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypothermic histidine‐tryptophan‐ketoglutarate (HTK) solution
Study: 24849441
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (medication group, 94 lesions)
Study: 22595272
Drug: Rapid diagnostic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid diagnostic tests (RDTs), artemether-lumefantrine (AL), amoxicillin
Study: 19019358
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g two times per day, n = 36)
Study: 19019358
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP) (35 microg ethinyl E(2)‐2 mg cyproterone acetate, n = 30)
Study: 12187499
Drug: Antiretrovirals alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretrovirals alone or in combination with HU and IL-2
Study: 8695837
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before mitoxantrone infusion)
Study: 8695837
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mitoxantrone 12 mg/m2/d, days 2 to 5 and cytarabine 1 g/m2/12 h, days 1 to 5)
Study: 1752115
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (intravenous)
Study: 30679284
Drug: Route of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of medication